Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Peripheral Artery Disease IV: Nursing Management

Peripheral Artery Disease IV: Nursing Management

The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026

Same author

Is supplemental vitamin D useful in the clinically isolated syndrome (CIS) typical of multiple sclerosis?

Expert opinion on pharmacotherapy·2026

Same author

Is seltorexant, an orexin-2 receptor antagonist, showing promise in insomnia?

Expert opinion on investigational drugs·2026

Same author

Does varenicline promote abstinence in youths who vape?

Expert opinion on pharmacotherapy·2025

Same author

Reply to: reframing guselkumab's benefit in ulcerative colitis: insights from QUASAR and emerging evidence.

Expert opinion on biological therapy·2025

Same author

With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?

Expert opinion on biological therapy·2025

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Clopidogrel use with stenting.

Sheila A Doggrell¹

¹Doggrell Biomedical Communications, 14 Quandong Crescent, Nightcliff, NT0810, Australia.

Expert Opinion on Pharmacotherapy

|June 15, 2007

Summary

Clopidogrel pretreatment before coronary stenting reduces adverse events. For drug-eluting stents, continue clopidogrel treatment for at least 24 months to prevent stent thrombosis and myocardial infarction.

Area of Science:

Cardiology
Pharmacology
Interventional Cardiology

Background:

Clopidogrel is established as beneficial in coronary artery stenting.
Optimal timing and duration of clopidogrel therapy post-stenting require further clarification.

Discussion:

A loading dose of clopidogrel (300 mg) 6-24 hours pre-intervention with 1-month maintenance reduced 30-day endpoints compared to maintenance alone.
No additional benefit of clopidogrel beyond 6 months was observed with bare-metal stents.
Long-term clopidogrel (≥24 months) significantly reduced death and myocardial infarction in patients with drug-eluting stents.

Key Insights:

Pre-stenting clopidogrel administration is recommended.
Duration of clopidogrel therapy should be tailored to stent type: 1 month for bare-metal stents and at least 24 months for drug-eluting stents.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Related Experiment Videos

Last Updated: Jul 14, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Extended clopidogrel use in drug-eluting stent recipients mitigates risks of stent thrombosis and ischemic events.

Outlook:

Further research may refine personalized clopidogrel treatment strategies based on patient risk factors and stent type.
Investigating novel antiplatelet agents or treatment durations could optimize outcomes in complex coronary stenting scenarios.
Long-term follow-up studies are crucial to fully understand the risk-benefit profile of extended clopidogrel therapy.